Literature DB >> 10533478

Liver tumours.

G Perilongo1, E A Shafford.   

Abstract

Primary hepatic tumours in children represent an heterogeneous group of neoplasms. Malignant tumours are more common (60% of primary liver tumours), but account for only 1.2-5% of all paediatric neoplasms. There are two main types of malignant tumour, those of epithelial origin, hepatoblastoma (HB) and hepatocellular carcinoma (HCC), and the rarer mesenchymal tumours, e.g. rhabdomyosarcoma and undifferentiated sarcoma, (Weinberg AG, Finegold, MJ. Primary hepatic tumours of childhood. Hum Pathol 1983, 14, 512-532). Vascular tumours e.g. haemangioendotheliomas are the most common of the benign tumours followed by mesenchymal hamartoma and the rare hepatic adenoma and focal nodular hyperplasia. This article will concentrate on the malignant epithelial tumours.

Entities:  

Mesh:

Year:  1999        PMID: 10533478     DOI: 10.1016/s0959-8049(99)00049-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

Review 1.  Hepatoblastoma--a rare liver tumor with review of literature.

Authors:  L Purnima Devi; Ritesh Kumar; Akash Handique; Mahendra Kumar
Journal:  J Gastrointest Cancer       Date:  2014-12

2.  Hepatoblastoma in a Young Adult: a Rare Case Report and Review of the Literature.

Authors:  Jeewan Ram Vishnoi; Ajai Sasidhar; Sanjeev Misra; Puneet Pareek; Sudeep Khera; Sushil Kumar; Ankit Jain
Journal:  J Gastrointest Cancer       Date:  2020-03

3.  Hepatoblastoma in a low birth weight infant : a case report and review of the literature.

Authors:  G Kaur; S S Mutum
Journal:  Malays J Med Sci       Date:  2001-01

4.  Nested stromal epithelial tumor of the liver--liver transplantation and follow-up.

Authors:  Merten Hommann; Daniel Kaemmerer; Wolfgang Daffner; Vikas Prasad; Richard Paul Baum; Alexander Petrovitch; Axel Sauerbrey; Katrin Katenkamp; Roland Kaufmann; Utz Settmacher
Journal:  J Gastrointest Cancer       Date:  2011-12

Review 5.  [MRT of the liver. Clinical significance of nonspecific and liver-specific MRT contrast agents].

Authors:  A Ba-Ssalamah; B Happel; J Kettenbach; A Dirisamer; F Wrba; F Längle; W Schima
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

Review 6.  Constitutional aneuploidy and cancer predisposition.

Authors:  Ithamar Ganmore; Gil Smooha; Shai Izraeli
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

Review 7.  Clinical value of MRI liver-specific contrast agents: a tailored examination for a confident non-invasive diagnosis of focal liver lesions.

Authors:  Ahmed Ba-Ssalamah; Martin Uffmann; Sanjai Saini; Nina Bastati; Christian Herold; Wolfgang Schima
Journal:  Eur Radiol       Date:  2008-09-23       Impact factor: 5.315

8.  A trend of improved survival of childhood hepatoblastoma treated with cisplatin and doxorubicin in Taiwanese children.

Authors:  Shuenn-Nan Chiu; Yen-Hsuan Ni; Meng-Yao Lu; Dong-Tsamn Lin; Kai-Hsin Lin; Hong-Shiee Lai; Mei-Hwei Chang
Journal:  Pediatr Surg Int       Date:  2003-10-11       Impact factor: 1.827

9.  Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma.

Authors:  Jian-Min Wu; Yan Xu; Nicholas J Skill; Hongmiao Sheng; Zhenwen Zhao; Menggang Yu; Romil Saxena; Mary A Maluccio
Journal:  Mol Cancer       Date:  2010-03-31       Impact factor: 27.401

10.  Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group.

Authors:  Allison F O'Neill; Alexander J Towbin; Mark D Krailo; Caihong Xia; Yun Gao; M Beth McCarville; Rebecka L Meyers; Eugene D McGahren; Greg M Tiao; Stephen P Dunn; Max R Langham; Christopher B Weldon; Milton J Finegold; Sarangarajan Ranganathan; Wayne L Furman; Marcio Malogolowkin; Carlos Rodriguez-Galindo; Howard M Katzenstein
Journal:  J Clin Oncol       Date:  2017-09-11       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.